Literature DB >> 29404686

Effects of haloperidol and clozapine on synapse-related gene expression in specific brain regions of male rats.

Martina von Wilmsdorff1, Fabian Manthey2, Marie-Luise Bouvier3, Oliver Staehlin4, Peter Falkai5, Eva Meisenzahl-Lechner1, Andrea Schmitt5,6, Peter J Gebicke-Haerter7,8.   

Abstract

We investigated the effects of clozapine and haloperidol, drugs that are widely used in the treatment of schizophrenia, on gene expression in six cortical and subcortical brain regions of adult rats. Drug treatments started at postnatal day 85 and continued over a 12-week period. Ten animals received haloperidol (1 mg/kg bodyweight) and ten received clozapine (20 mg/kg bodyweight) orally each day. Ten control rats received no drugs. The ten genes selected for this study did not belong to the dopaminergic or serotoninergic systems, which are typically targeted by the two substances, but coded for proteins of the cytoskeleton and proteins belonging to the synaptic transmitter release machinery. Quantitative real-time PCR was performed in the prelimbic cortex, cingulate gyrus (CG1) and caudate putamen and in the hippocampal cornu ammonis 1 (CA1), cornu ammonis 3 (CA3) and dentate gyrus. Results show distinct patterns of gene expression under the influence of the two drugs, but also distinct gene regulations dependent on the brain regions. Haloperidol-medicated animals showed statistically significant downregulation of SNAP-25 in CA3 (p = 0.0134) and upregulation of STX1A in CA1 (p = 0.0133) compared to controls. Clozapine-treated animals showed significant downregulation of SNAP-25 in CG1 (p = 0.0013). Our results clearly reveal that the drugs' effects are different between brain regions. These effects are possibly indirectly mediated through feedback mechanisms by proteins targeted by the drugs, but direct effects of haloperidol or clozapine on mechanisms of gene expression cannot be excluded.

Entities:  

Keywords:  BDNF; Cytoskeletal proteins; Gene expression; Presynaptic proteins; Schizophrenia

Mesh:

Substances:

Year:  2018        PMID: 29404686     DOI: 10.1007/s00406-018-0872-8

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  41 in total

Review 1.  Neurotransmitter interactions in schizophrenia--therapeutic implications.

Authors:  A Carlsson; N Waters; M L Carlsson
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

Review 2.  Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia.

Authors:  P J Harrison; S L Eastwood
Journal:  Hippocampus       Date:  2001       Impact factor: 3.899

3.  Detection of behavioral alterations and learning deficits in mice lacking synaptophysin.

Authors:  U Schmitt; N Tanimoto; M Seeliger; F Schaeffel; R E Leube
Journal:  Neuroscience       Date:  2009-04-22       Impact factor: 3.590

4.  A meta-analysis of peripheral blood nerve growth factor levels in patients with schizophrenia.

Authors:  X-Y Qin; H-T Wu; C Cao; Y P Loh; Y Cheng
Journal:  Mol Psychiatry       Date:  2017-01-10       Impact factor: 15.992

5.  A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia.

Authors:  Mie A Rizig; Andrew McQuillin; Aylwin Ng; Michelle Robinson; Andrew Harrison; Marketa Zvelebil; Steve P Hunt; Hugh M Gurling
Journal:  J Psychopharmacol       Date:  2012-07-05       Impact factor: 4.153

6.  Selective effects of typical antipsychotic drugs on SNAP-25 and synaptophysin in the hippocampal trisynaptic pathway.

Authors:  Alasdair M Barr; Clint E Young; Anthony G Phillips; William G Honer
Journal:  Int J Neuropsychopharmacol       Date:  2005-09-05       Impact factor: 5.176

7.  The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model.

Authors:  M von Wilmsdorff; M L Bouvier; U Henning; A Schmitt; T Schneider-Axmann; W Gaebel
Journal:  Pharmacopsychiatry       Date:  2012-08-22       Impact factor: 5.788

8.  Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.

Authors:  Julie Minet-Ringuet; Patrick C Even; Marc Goubern; Daniel Tomé; Renaud de Beaurepaire
Journal:  Appetite       Date:  2006-03-23       Impact factor: 3.868

9.  Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration.

Authors:  Jennifer Chlan-Fourney; Paula Ashe; Kirk Nylen; Augusto V Juorio; Xin Min Li
Journal:  Brain Res       Date:  2002-11-01       Impact factor: 3.252

10.  Altered gene expression in the superior temporal gyrus in schizophrenia.

Authors:  Nikola A Bowden; Rodney J Scott; Paul A Tooney
Journal:  BMC Genomics       Date:  2008-04-29       Impact factor: 3.969

View more
  3 in total

1.  CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects.

Authors:  Chengai Xu; Carl M Sellgren; Helena Fatouros-Bergman; Fredrik Piehl; Kaj Blennow; Henrik Zetterberg; Ann Brinkmalm; Alexander Frizell Santillo; Sofia Lundgren; Simon Cervenka; Göran Engberg; Sophie Erhardt
Journal:  IBRO Rep       Date:  2020-04-13

2.  Influence of clozapine on neurodevelopmental protein expression and behavioral patterns in animal model of psychiatric disorder induced by low-level of lead.

Authors:  Hwayoung Lee; Minyoung Lee; Hyung-Ki Kim; Young Ock Kim; Jun-Tack Kwon; Hak-Jae Kim
Journal:  Korean J Physiol Pharmacol       Date:  2019-10-24       Impact factor: 2.016

3.  COMT, 5-HTR2A, and SLC6A4 mRNA Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association With Treatment Outcomes.

Authors:  Zongchang Li; Ying He; Hongying Han; Yao Zhou; Xiaoqian Ma; Dong Wang; Jun Zhou; Honghong Ren; Liu Yuan; Jinsong Tang; Xiaofen Zong; Maolin Hu; Xiaogang Chen
Journal:  Front Psychiatry       Date:  2018-11-13       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.